ECHO IQ LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.105 AUD | 0.00% |
|
0.00% | -38.24% |
| 04-02 | Echo IQ CEO Steps Down; Chairman Named Interim Successor | MT |
| 03-21 | Careteq Appoints CEO; Shares Down 6% | MT |
| Sales 2022 | 251K 164K 224K | Sales 2023 | 107K 70.11K 95.75K | Capitalization | 70.84M 46.27M 63.2M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -3.27M -4.46M | Net income 2023 | -7M -4.57M -6.24M | EV / Sales 2022 | 175 x |
| Net cash position 2022 | 2.41M 1.57M 2.15M | Net cash position 2023 | 3.28M 2.14M 2.92M | EV / Sales 2023 | 629 x |
| P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-8.56
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.46% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -30.00% | ||
| 1 month | -6.67% | ||
| 3 months | -27.59% | ||
| 6 months | -44.74% | ||
| Current year | -38.24% |
1 week
0.10
0.11
1 month
0.100.15
Current year
0.100.17
1 year
0.100.23
3 years
0.070.23
5 years
0.010.23
10 years
0.011.15
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Grover
CEO | Chief Executive Officer | - | 19-05-23 |
Seán Bryceland
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-28 |
Philip Woolff
COO | Chief Operating Officer | - | 21-11-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Picton
BRD | Director/Board Member | - | 21-10-19 |
Steven Formica
BRD | Director/Board Member | 64 | 18-07-01 |
| - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.105 | 0.00% | 263,805 |
| 24-04-24 | 0.105 | 0.00% | 305,948 |
| 24-04-23 | 0.105 | +5.00% | 55,560 |
| 24-04-22 | 0.1 | -4.76% | 250,034 |
| 24-04-19 | 0.105 | 0.00% | 195,468 |
Delayed Quote Australian S.E., April 26, 2024 at 12:50 am
More quotes
EchoIQ Limited (ECHOiQ) is an Australia-based health and medical technology company. The Company is engaged in the product development, marketing and commercialization of software products and services. It provides cardiac diagnostics technology. The Company has developed cloud-based decision-support software, EchoSolv, powered by artificial intelligence (AI) and machine learning, which aims to provide physicians with a reliable tool to identify patients at-risk of structural heart disease. ECHOiQâs technology uses AI assisted diagnostics to deliver real-world health solutions. Its screening program uses an AI backed system and access to cardiac big data that identifies patients at risk from aortic stenosis and other forms of structural heart disease. The Company's technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -38.24% | 33.91M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.15B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- EIQ Stock
